38,324 Shares in Ingevity Corporation $NGVT Purchased by Deutsche Bank AG

Key Points

• Deutsche Bank acquired 38,324 Ingevity shares during the second quarter, worth approximately $2.86 million and representing about 0.11% of the company. Institutional investors collectively own 91.59% of NGVT.
• Analysts maintain a consensus “Hold” rating with an average price target of $80; two analysts rate the stock Buy and three rate it Hold.
• Ingevity beat quarterly earnings expectations, reporting $1.74 EPS versus $1.33 expected and revenue of $314.1 million. Meanwhile, company insiders sold 17,801 shares worth about $1.35 million over the past 90 days.

Deutsche Bank AG bought a new stake in Ingevity Corporation (NYSE:NGVT - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 38,324 shares of the company's stock, valued at approximately $2,862,000. Deutsche Bank AG owned about 0.11% of Ingevity as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Assetmark Inc. boosted its stake in shares of Ingevity by 9.6% in the first quarter. Assetmark Inc. now owns 1,584 shares of the company's stock worth $113,000 after buying an additional 139 shares during the last quarter. Advisory Services Network LLC lifted its holdings in Ingevity by 4.4% in the third quarter. Advisory Services Network LLC now owns 6,947 shares of the company's stock valued at $383,000 after acquiring an additional 293 shares during the period. Amundi lifted its holdings in Ingevity by 4.8% in the third quarter. Amundi now owns 6,626 shares of the company's stock valued at $364,000 after acquiring an additional 302 shares during the period. Isthmus Partners LLC boosted its position in Ingevity by 0.5% in the 4th quarter. Isthmus Partners LLC now owns 72,245 shares of the company's stock worth $4,275,000 after purchasing an additional 375 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its position in Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company's stock worth $36,000 after purchasing an additional 387 shares in the last quarter. Institutional investors and hedge funds own 91.59% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on NGVT shares. Wall Street Zen lowered shares of Ingevity from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 1st. Weiss Ratings raised shares of Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, July 31st. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Ingevity currently has a consensus rating of "Hold" and an average target price of $80.00.

Insider Buying and Selling at Ingevity

In related news, CEO David H. Li sold 5,000 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $75.83, for a total transaction of $379,150.00. Following the completion of the transaction, the chief executive officer owned 120,636 shares in the company, valued at $9,147,827.88. This represents a 3.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ryan C. Fisher sold 2,709 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $73.72, for a total transaction of $199,707.48. Following the completion of the transaction, the senior vice president directly owned 15,722 shares in the company, valued at $1,159,025.84. This represents a 14.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 17,801 shares of company stock worth $1,347,481. Insiders own 0.88% of the company's stock.

Ingevity Stock Up 0.8%

Shares of NGVT opened at $69.57 on Thursday. The firm has a market cap of $2.39 billion, a P/E ratio of 47.33 and a beta of 1.16. Ingevity Corporation has a 12 month low of $45.85 and a 12 month high of $79.29. The stock's 50 day moving average is $73.68 and its two-hundred day moving average is $71.83. The company has a current ratio of 1.61, a quick ratio of 1.15 and a debt-to-equity ratio of 22.52.

Ingevity (NYSE:NGVT - Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.33 by $0.41. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.The firm had revenue of $314.10 million for the quarter, compared to analyst estimates of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Analysts predict that Ingevity Corporation will post 5.4 earnings per share for the current fiscal year.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source